Adherence to Antimalarial Therapy Reduces Risk for Type 2 Diabetes in SLE
Adherence to antimalarial therapy can provide a protective effect against the development of type 2 diabetes in patients with systemic lupus erythematosus.
Systemic Lupus Erythematosus
SYSTEMIC LUPUS ERYTHEMATOSUS
-
-
Increased S aureus Colonization in Skin Lesions Among Patients With Lupus
Patients with systemic lupus erythematosus (SLE) have increased colonization with Staphylococcus aureus in cutaneous lupus erythematosus lesions. -
Renal Arteriosclerosis Common But Underreported in Lupus Nephritis
Researchers examined the burden of renal arteriosclerosis in lupus nephritis (LN), and they also assessed whether arteriosclerosis was underreported in LN biopsies. -
Chronic Damage Not Affected by Pregnancy in Systemic Lupus Erythematosus
Researchers evaluated the chronic damage associated with pregnancies before and after the diagnosis of systemic lupus erythematosus. -
Neuropsychiatric Events Most Frequently Occur at SLE Diagnosis
Researchers examined the association between neuropsychiatric events and health-related quality of life in a cohort of patients with systemic lupus erythematosus. -
Visual Analog Scale Assessments Can Reliably Assess Disease Severity in SLE
Researchers compared the performance of 2 visual analog scale-based assessments, SSPGA and LFA-REAL, with outcome measures from other lupus trials. -
Renal Arteriosclerosis Develops Prematurely in Lupus Nephritis
A study found that renal arteriosclerosis develops 2 decades earlier in patients with lupus nephritis compared with healthy age-matched controls. -
High Genetic Risk Score Associated With Organ Damage, Renal Dysfunction, and All-Cause Mortality in SLE
The study evaluated the association between high genetic disease risk and disease severity in patients with systemic lupus erythematosus. -
Peripheral Nervous System Disease Has Significant Negative Effect on Quality of Life in SLE
Peripheral nervous system (PNS) disease is a component of systemic lupus erythematosus (SLE) disease activity and has a significant negative impact on health-related quality of life. -
Antimalarial Drugs May Reduce Polyautoimmunity in Systemic Lupus Erythematosus
Researchers evaluated the frequency of polyautoimmunity and its associated factors in a large retrospective cohort of patients with systemic lupus erythematosus.
LATEST NEWS
Anti-Carbamylated Protein Antibodies Linked to SLE Disease Activity
Researchers evaluated levels of serum anti-carbamylated protein antibodies and assessed their clinical value in systemic lupus erythematosus.
Belimumab Associated With Meaningful Improvement in Lupus Nephritis Trial
GlaxoSmithKline announced positive results from the phase 3 BLISS-LN trial of belimumab for the treatment of active lupus nephritis in adult patients.
Anifrolumab Improves Response at 52 Weeks in Lupus
For patients with systemic lupus erythematosus (SLE), anifrolumab is associated with improved response at 52 weeks versus placebo.
Itolizumab Receives Fast Track Status for Lupus Nephritis
The FDA has granted Fast Track designation for itolizumab (EQ001; Equillium) for the treatment of lupus nephritis.
No Significant Effect of Belimumab on Levels of Certain Anticardiolipin Antibodies in SLE
Researchers assessed the effect of belimumab vs placebo on antiphospholipid antibodies from 2 large randomized controlled trials, BLISS-76 and BLISS-52.
Voclosporin Superior to Standard of Care in Lupus Nephritis Trial
Voclosporin was found to be superior to standard-of-care treatment in patients with lupus nephritis, according to data from the phase 3 AURORA trial.
Newly Diagnosed SLE Associated With Increased Risk for Hip Fractures
Researchers assessed the independent risk of hip fractures in patients with newly diagnosed systemic lupus erythematosus compared with the general population.
Atrial Fibrillation Hospitalization Rate Twice as High in Medicaid Recipients With SLE
Researchers investigated and compared the rates, risks, and risk factors for atrial fibrillation among Medicaid recipients with systemic lupus erythematosus (SLE) and age- and sex-matched Medicaid recipients without SLE.
Anifrolumab Superior to Placebo in Moderate to Severe Systemic Lupus Erythematosus
Although the first phase 3 trial of anifrolumab did not meet its primary end point, other study end points that were met suggested a clinical benefit for the monoclonal antibody in systemic lupus erythematosus.
Glucocorticoid Use Associated With Increased Risk for Cardiovascular Disease in SLE
Researchers addressed the association between cardiovascular risk and glucocorticoids in patients with systemic lupus erythematosus.
Want to read more?
Please login or register first to view this content.
Next post in Systemic Lupus Erythematosus
